Adolescents and young adults on TMP-SMX have a higher 30-day risk of acute respiratory failure than those on amoxicillin or cephalosporins. The study supports the FDA's warning about TMP-SMX, with ...
Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback